Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- digit pain/discomfort
- digital paresthesia
- pallor of digits
- red and/or blue discoloration of digits
- dilated capillaries at nailbeds
- well-defined discoloration
- magnification of nailbeds
Otros factores de diagnóstico
- heartburn
- dysphagia
- puffy hands
- tight skin
- arthralgia
- photosensitivity
- oral/nasal ulcers
- alopecia
- butterfly rash
- sclerodactyly
- telangiectasia
- pleuritic chest pain
- digital ulcers
- digital pits
- digital tuft resorption
- gangrene of fingertip/finger
- raised painful red lesions on finger tips
- autoamputation
Factores de riesgo
- female
- family history
- connective tissue disease
- use of certain drugs
- vibration injury
- Buerger disease
- prolonged cold exposure/frostbite
- colder climate
- smoking
- ischemia
- migraine
- glaucoma
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- clinical diagnosis
- antinuclear antibody
- CBC
- erythrocyte sedimentation rate
- C-reactive protein
- urinalysis
Pruebas diagnósticas que deben considerarse
- capillaroscopy
Algoritmo de tratamiento
severe secondary RP: critical ischemia with digital ulcers or threatened digital loss
primary or mild secondary RP
Colaboradores
Autores
Janet Pope, MD, MPH, FRCPC

Professor of Medicine
Division of Rheumatology
Department of Medicine
University of Western Ontario
Schulich School of Medicine and Dentistry
Head
Division of Rheumatology
St. Joseph's Health Care
London
Ontario
Canada
Divulgaciones
JP has been reimbursed for consulting with several pharmaceutical manufacturers unrelated to Rayaud phenomenon. JP’s institution receives research grants from BMS, Janssen, and Seattle Genetics. She has acted as a consultant for AbbVie, Amgen, AstraZeneca, BI, BMS, Celltrion, EMERALD, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Organon, Pfizer, Sandoz, Samsung, and Viatris. JP is a speaker and advisory board member for AbbVie, Amgen, AstraZeneca, BI, BMS, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Novartis, Organon, Pfizer, Sandoz, UCB, and Viatris. She receives no patents or royalties. JP is an author of a number of references cited in this topic.
Revisores por pares
Elena Schiopu, MD
Professor of Medicine
Rheumatologist
Medical College of Georgia at Augusta University
Charlie Norwood Veterans Affairs Medical Center
Augusta
GA
Divulgaciones
ES declares that she has no competing interests.
Ariane L. Herrick, MD FRCP
Reader in Rheumatology and Consultant Rheumatologist
Musculoskeletal Research Group
University of Manchester
Manchester
UK
Divulgaciones
ALH has been a paid speaker for Actelion; a consultant for Actelion and Pfizer; and an investigator in studies sponsored by Actelion, Mediquest, and United Therapeutics. ALH is an author of a number of references cited in this topic.
Bridget Griffiths, MB ChB, MD, MRCP(UK)
Consultant Rheumatologist
Department of Rheumatology
Freeman Hospital
Newcastle upon Tyne
UK
Divulgaciones
BG declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referencias
Artículos principales
Curtiss P, Svigos K, Schwager Z, et al. Part I: epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol. 2024 Feb;90(2):223-34. Resumen
Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23.Texto completo Resumen
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Normal response to cold
- Cyanosis/cryoglobulinemia
- Chilblains (perniosis)
Más DiferencialesGuías de práctica clínica
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis
- EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
Más Guías de práctica clínicaFolletos para el paciente
Quitting smoking
Raynaud phenomenon
Mais Folletos para el pacienteConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal